1029P Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)

Anthony J. Olszanski, Xīn Gào, Patricia LoRusso et al.|Annals of Oncology|2023

Cited by 14